Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Wednesday announced progress in the design and planning of its upcoming Phase 3 trial evaluating AD04, the company's lead investigational genetically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback